Eris to buy Strides Shasun's India branded biz for Rs 500 cr

Updated: Sat, Nov 18, 2017
04:58 pm
PTI
RELATED NEWS
China's Tencent Music raises nearly $1.1 billion in U.S. IPO China's Tencent Music raises nearly $1.1 billion in U.S. IPO
S&P 500, Dow edge lower as U.S. shutdown threat, China trade in focus S&P 500, Dow edge lower as U.S. shutdown threat, China trade in focus
Google has no plans to launch search engine in China: Sunder Pichai Google has no plans to launch search engine in China: Sunder Pichai

Ahmedabad-based drug maker Eris Lifesciences has entered into a definitive pact with Bengaluru-Based Strides Shasun to acquire latter's India branded generics business for a cash consideration of Rs 500 crore.

"The transaction is subject to customary closing conditions and parties intend to close the transaction by November 30, 2017," the companies said in a joint statement.

Strides' India branded generics business comprises a portfolio of over 130 brands in the domains of neurology, psychiatry, nutraceuticals and Gastro, among others, it added.

"Along with the brands, the employees of Strides' India branded generics business will also become a part of Eris, but the exact numbers have to be worked out," Eris Lifesciences MD Amit Bakshi told

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close